Die Rolle von Faktor XIII bei kardiound zerebrovaskulären Erkrankungen

H.P. Kohler; V. Schröder

doi:10.1055/s-0037-1622007

Hämostaseologie, Table of Contents

Hamostaseologie 2002; 22(01): 39-44
DOI: 10.1055/s-0037-1622007

Original Article

Schattauer GmbH

Die Rolle von Faktor XIII bei kardiound zerebrovaskulären Erkrankungen

Role of coagulation factor XIII in cardioand cerebrovascular diseases

Authors

H.P. Kohler
V. Schröder

¹Thromboselabor (Laborleitung: Prof. Dr. phil. nat. A. Haeberli) Departement Klinische Forschung, Universität Bern Inselspital, 3010 Bern, Schweiz

Abstract

Zusammenfassung

Am Ende der Gerinnungskaskade aktiviert Thrombin den Blutgerinnungsfaktor XIII (FXIII). Das aktivierte Enzym (FXIIIa) überführt lösliches Fibrin in quervernetztes, unlösliches Fibrin. Die Rolle von FXIII bei der Entstehung kardio- und zerebrovaskulärer Erkrankungen wird erst seit kurzem untersucht. Der häufig vorkommende FXIII-Val34Leu-Polymorphismus im Gen der FXIII-A-Untereinheit hat zwar einen protektiven Effekt gegen Herz- und ischämischen Hirninfarkt, ist aber auch mit einem erhöhten Risiko für hämorrhagischen zerebrovaskulären Insult verbunden. Vermutlich schützt FXIII-Val34Leu auch vor Lungenembolie und tiefer Beinvenenthrombose. Als mögliche Mechanismen werden die vorzeitige Elimination des mutierten FXIIIa aus der Zirkulation sowie veränderte Strukturen der durch den mutierten FXIIIa vernetzten Gerinnsel diskutiert. Auch aufgrund der Interaktion zwischen FXIII und dem Insulinresistenzsyndrom, also der Wechselwirkung zwischen Komponenten der Blutgerinnung und klassischen metabolischen atheromatösen Risikofaktoren, muss FXIII als weiterer Gerinnungsfaktor betrachtet werden, der zu den komplexen Gen-Umwelt-Wechselwirkungen beiträgt, denen pathogenetische Bedeutung bei kardio- und zerebrovaskulären sowie thromboembolischen Erkrankungen zukommt.

Summary

In the final step of the clotting cascade coagulation factor XIII (FXIII) is activated by thrombin. The activated enzyme (FXIIIa) has an important role in the final stage of blood coagulation in cross-linking soluble fibrin to a stable insoluble clot. The role of FXIII in cardio- and cerebrovascular diseases has been investigated recently. The widespread Val34Leu polymorphism in the gene coding for the FXIII subunit A (FXIII Val34Leu) has been shown to protect against myocardial infarction and ischemic stroke, but is also associated with an increased risk for hemorrhagic stroke. Additionally, FXIII Val34Leu is supposed to be protective against pulmonary embolism and deep vein thrombosis. As possible mechanisms for the antithrombotic effect, premature depletion of the mutant protein from circulation and altered fibrin structures of clots cross-linked by the mutant FXIIIa are under discussion. The connection between FXIII and the insulin resistance syndrome also attracts attention, i. e. the interaction between a component of the coagulation cascade and thus a thrombotic risk factor and classical atheromatous risk factors. Therefore, FXIII must be considered as another coagulation factor contributing to complex interactions between genes and environment important for the pathogenesis of cardio- and cerebrovascular and thromboembolic diseases.

Schlüsselwörter

Faktor XIII - FXIII-Val34Leu-Polymorphismus - Insulinresistenzsyndrom

Keywords

Factor XIII - FXIII Val34Leu polymorphism - insulin resistance syndrome

Full Text

References

Literatur
1 Aeschlimann D, Mosher DF, Paulsson M. Tissue transglutaminase and factor XIII in cartilage and bone remodeling. Semin Thromb Hemost 1996; 22: 437-43.
2 Alhenc-Gelas M, Rény JL, Aubry ML. et al. The FXIII Val34Leu mutation and the risk of venous thrombosis. Thromb Haemost 2000; 84: 1117-8.
3 Anwar R, Gallivan L, Edmonds SD. et al. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood 1999; 93: 897-905.
4 Anwar R, Stewart AD, Miloszewski KJA. et al. Molecular basis of inherited factor XIII deficiency: identification of multiple mutations provides insights into protein function. Br J Haematol 1995; 91: 728-35.
5 Ariëns RAS, Kohler HP, Mansfield MW. et al. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension. Arterioscler Thromb Vasc Biol 1999; 19: 2012-6.
6 Ariëns RAS, Philippou H, Chandrasekaran N. et al The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-95.
7 Attié-Castro FA, Zago MA, Lavinha J. et al. Ethnic heterogeneity of the factor XIII Val34Leu polymorphism. Thromb Haemost 2000; 84: 601-3.
8 Atwa AAA, Grant PJ, Ariëns RAS. Effect of the FXIII Val34Leu polymorphism on the interaction between platelets and cross-linked fibrin. ISTH Paris. 2001 Thromb Haemost (Suppl) 2001, OC2485
9 Balogh I, Szôke G, Kárpáti L. et al. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood 2000; 96: 2479-86.
10 Barkan G, Gaspar A. Zur Frage der Reversibilität der Fibringerinnung. Biochem Z 1923; 139: 291-301.
11 Canavy I, Henry M, Morange PE. et al. Genetic polymorphisms and coronary artery disease in the south of France. Thromb Haemost 2000; 83: 212-6.
12 Carter AM, Catto AJ, Grant PJ. The association of the α-fibrinogen Thr312Ala polymorphismus with post-stroke mortality in subjects with atrial fibrillation. Circulation 1999; 99: 2423-6.
13 Carter AM, Catto AJ, Kohler HP. et al. α-Fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood 2000; 96: 1177-9.
14 Catto AJ, Kohler HP, Bannan S. et al. Factor XIII Val34Leu: a novel association with primary intracerebral hemorrhage. Stroke 1998; 29: 813-6.
15 Catto AJ, Kohler HP, Coore J. et al. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93: 906-8.
16 Corral J, Gonzales-Conejero R, Iniesta JA. et al. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica 2000; 85: 293-7.
17 Corral J, Iniesta JA, González-Conejero R. et al. Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. Blood 2001; 97: 2979-82.
18 De Lange M, Snieder H, Ariëns RAS. et al. The genetics of haemostasis: a twin study. Lancet 2001; 357: 101-5.
19 Ehrenforth S, Krause M, Herrmann FH. et al. Pathogenesis of primary pulmonary embolism: impact of the FXIIIVal34Leu polymorphism. Haemostasis 2000 30: 36 [abstract].
20 Elbaz A, Poirier O, Canaple S. et al. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-91.
21 Francis RT, McDonagh J, Mann XG. Factor V is a substrate for the transamidase factor XIIIa. J Biol Chem 1986; 261: 9787-92.
22 Franco RF, Middeldorp S, Meinardi JR. et al. Factor XIII Val34Leu and the risk of venous thromboembolism in factor V Leiden carriers. Br J Haematol 2000; 111: 118-21.
23 Franco RF, Pazin-Filho A, Tavella MH. et al. Factor XIII Val34Leu and the risk of myocardial infarction. Haematologica 2000; 85: 67-71.
24 Franco RF, Reitsma PH, Lourenço D. et al. Factor XIIIVal34Leu is a genetic factor involved in the aetiology of venous thrombosis. Thromb Haemost 1999; 81: 676-9.
25 Gemmati D, Serino ML, Ongaro A. et al. A common mutation in the gene for coagulation factor XIII-A (Val34Leu): A risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am J Hematol 2001; 67: 183-8.
26 Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional crosslinking enzymes that stabilize tissue. FASEB J 1991; 5: 3071-7.
27 Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A-subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998; 92: 2766-70.
28 Kimura S, Aoki N. Cross-linking site in fibrinogen for α₂-plasmin inhibitor. J Biol Chem 1986; 261: 15591-5.
29 Kohler HP, Ariëns RAS, Whitaker P. et al. A common coding polymorphism in the factor XIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity. Thromb Haemost 1998; 80: 704.
30 Kohler HP, Ariëns RAS, Whitaker P. et al. Factor XIII activity and antigen levels in patients with coronary artery disease. Interaction with FXIIIVal34Leu. Thromb Haemost 2001; 85: 569-70.
31 Kohler HP, Carter AM, Stickland MH. et al. Levels of activated factor XII in survivors of myocardial infarction.Association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 1998; 79: 14-8.
32 Kohler HP, Futers TS, Grant PJ. Prevalence of three common polymorphisms in the A-subunit gene of FXIII in patients with coronary artery disease. Association with FXIII activity and antigen levels. Thromb Haemost 1999; 81: 511-5.
33 Kohler HP, Futers TS, Grant PJ. FXII (46C(T) polymorphism and in vivo generation of FXII activity. Thromb Haemost 1999; 81: 745-7.
34 Kohler HP, Grant PJ. Clustering of FXIIIVal34Leu with haemostatic risk factors. Thromb Haemost 1998; 80: 862.
35 Kohler HP, Grant PJ. Plasminogen activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-1801.
36 Kohler HP, Mansfield MW, Clark PS. et al. Interaction between insulin resistance and factor XIIIVal34Leu in patients with coronary artery disease. Thromb Haemost 1999; 82: 1202-3.
37 Kohler HP, Stickland MH, Ossei-Gerning N. et al. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
38 Lorand L. Fibrin clots. Some properties of the “serum factor”. Nature 1950; 166: 694-6.
39 Lorand L, Chenoweth D, Gray A. Titration of the acceptor cross-linking sites in fibrin. Ann NY Acad Sci 1972; 202: 155-71.
40 Mansfield MW, Kohler HP, Ariëns RAS. et al. Circulating levels of coagulation factor XIII in subjects with type 2 diabetes and their firstdegree relatives. Diabetes Care 2000; 23: 703-4.
41 Margaglione M, Bossone A, Brancaccio V. et al. Factor XIII Val34Leu polymorphism and risk of deep vein thrombosis. Thromb Haemost 2000; 84: 1118-9.
42 McCormack LJ, Kain K, Catto AJ. et al. Prevalence of FXIIIV34L in populations with different cardiovascular risk. Thromb Haemost 1998; 80: 523-4.
43 Mikkola H, Syrjala M, Rasi V. et al. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood 1994; 84: 517-25.
44 Morange PE, Henry M, Brunet D. et al. Factor XIIIV34L is not an additional genetic risk factor for venous thrombosis in factor V Leiden carriers. Blood 2001; 97: 1894-5.
45 Mosher DF, Schad PE, Kleinmann HK. Cross-linking of fibronectin to collagen by blood coagulation factor XIIIa. J Clin Invest 1979; 64: 781-7.
46 Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
47 Renner W, Köppel H, Hoffmann C. et al. Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria. Thromb Res 2000; 99: 35-9.
48 Sadasivan C, Yee VC. Interaction of the factor XIII activation peptide with α-thrombin. J Biol Chem 2000; 275: 36942-8.
49 Saha N, Aston CE, Low PS. et al. Racial and genetic determinants of plasma factor XIII activity. Genet Epidemiol 2000; 19: 440-55.
50 Schröder V, Kohler HP. Effects of factor XIII Val34Leu on α₂-antiplasmin incorporation into fibrin. Thromb Haemost 2000; 84: 1128-30.
51 Schwarz ML, Oizzo SV, Hill RL. et al. Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem 1973; 248: 1359-407.
52 Suzuki K, Henke J, Iwata M. et al. Novel polymorphisms and haplotypes in the human coagulation factor XIII A-subunit gene. Hum Genet 1996; 98: 393-5.
53 Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIIIVal34Leu mutation. J Biol Chem 2000; 275: 20627-31.
54 Valnickova Z, Enghild JJ. Human procarboxypeptidase U, or thrombin-activatable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem 1998; 273: 27220-4.
55 Wartiovaara U, Perola M, Mikkola H. et al. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Arteriosclerosis 1999; 142: 295-300.
56 Yorifuji H, Anderson K, Lynch GW. et al. B protein of factor XIII: differentiation between free B and complexed B. Blood 1988; 72: 1645-50.